These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22647228)

  • 1. [Merkel cell carcinoma during treatment with TNF-alpha inhibitors: coincidence or warning?].
    Linn-Rasker SP; van Albada-Kuipers GA; Dubois SV; Janssen K; Zweers PG
    Ned Tijdschr Geneeskd; 2012; 156(22):A4464. PubMed ID: 22647228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Merkel cell carcinoma in a patient treated with adalimumab: case report.
    Krishna SM; Kim CN
    Cutis; 2011 Feb; 87(2):81-4. PubMed ID: 21416774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
    Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
    Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
    Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 10. Pancolitis during etanercept treatment of rheumatoid arthritis relapsing on the administration of further two TNF-alpha inhibitors.
    Actis GC; Lagget M; Pellicano R; Rosina F
    Int J Colorectal Dis; 2012 Apr; 27(4):547-8. PubMed ID: 21656142
    [No Abstract]   [Full Text] [Related]  

  • 11. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.
    Kekow J; Welte T; Kellner U; Pap T
    Arthritis Rheum; 2002 Mar; 46(3):843-4. PubMed ID: 11920425
    [No Abstract]   [Full Text] [Related]  

  • 13. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
    Toussirot E; Berthelot JM; Pertuiset E; Bouvard B; Gaudin P; Wendling D; le Noach J; Lohse A; Lecuyer E; Cri L
    J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Scott DL; Kingsley GH
    N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
    J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.
    Atzeni F; Sarzi-Puttini P; Botsios C; Carletto A; Cipriani P; Favalli EG; Frati E; Foschi V; Gasparini S; Giardina A; Gremese E; Iannone F; Sebastiani M; Ziglioli T; Biasi D; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Gorla R; Govoni M; Lapadula G; Marchesoni A; Salaffi F; Punzi L; Triolo G; Ferraccioli G
    Autoimmun Rev; 2012 Dec; 12(2):225-9. PubMed ID: 22796281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
    Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
    Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
    Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
    J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.